CB1 Hartzaile kanabinoidearen azalpena saguaren garuneko zelula oligodendroglialetan

  1. Andrea Manterola
  2. Ana Bernal-Chico
  3. Susana Mato
Llibre:
Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.
  1. Olatz Arbelaitz (coord.)
  2. Ainhoa Latatu (coord.)
  3. Miren Josu Omaetxebarria (coord.)
  4. Blanca Urgell (coord.)

Editorial: Udako Euskal Unibertsitatea, UEU = Universidad Vasca de Verano

ISBN: 978-84-8438-789-3

Any de publicació: 2021

Pàgines: 135-142

Congrés: Ikergazte. Nazioarteko Ikerketa Euskaraz (4. 2021. null)

Tipus: Aportació congrés

Resum

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous systemwhere focal lesions lead to neuronal damage. This neurodegenerative disorder induces disabilities inyoung adults. It is well stablished that the ability of oligodendrocyte precursor cells (OPCs) todifferentiate into myelinating oligodendrocytes (OLs) alleviates the symptomatology. OPC maturationand remyelination are key therapeutic strategies in MS. In this sense, manipulation of theendocannabinoid system in OLs and OPCs seems promising. Although CB1 receptor activation inoligodendroglial cells shows therapeutic potential, reliable demonstration of the presence of thereceptor in these cell lineage in situ remains elusive.